ARTICLE | Clinical News
Avax announces interim Phase II data
March 15, 2000 8:00 AM UTC
AVXT said data from 23 patients in its Phase II low-dose study of its M-Vax cancer vaccine to treat post-surgical metastatic melanoma showed that 65 percent of patients had an immune response as measu...